Overview
Portfolio
More
Oxfordtechnology
Oxford, United Kingdom
Enables investors to access cutting‑edge technology start‑ups through tax‑efficient SEIS and EIS funds and manages four Oxford Technology VCTs, specializing in technology investments since 1983.
Portfolio
49+
Employees
10+
Founded
1983
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedGeographic scope
Europe
Fund details
Funds
SEIS and EIS Start-Up Fund
Knowledge-Intensive EIS Fund
Sources
Oxfordtechnology
Enables investors to access cutting‑edge technology start‑ups through tax‑efficient SEIS and EIS funds and manages four Oxford Technology VCTs, specializing in technology investments since 1983.
Portfolio
49+
Employees
10+
Founded
1983
AUM
N/A
Funds
SEIS and EIS Start-Up Fund
Knowledge-Intensive EIS Fund
Stages
No stages listed
Industries
No industries listedGeographic scope
Europe
Sources
Showing 24 of 33 matched portfolio companies
Active Needle Technology develops a precision needle targeting system that utilizes Doppler ultrasound to enhance visibility and control during interventional procedures, such as cancer biopsies and drug delivery. This technology reduces needle penetration forces and minimizes the risk of misplaced procedures, leading to improved patient outcomes and lower healthcare costs.
Funding: $3.2M
Rough estimate of the amount of funding raised
Funding: $3.2M
Rough estimate of the amount of funding raised
The startup offers a digital platform for e-books and audiobooks specifically in South Slavic languages, providing users with access to a diverse range of literary content. This addresses the limited availability of such resources, enhancing cultural accessibility and language preservation for speakers of these languages.
The startup has developed a cell preservation technology that utilizes alginate hydrogels to encapsulate cells and tissues, allowing for safe storage and transport at room temperature. This method protects biological products from biochemical and physical damage, ensuring their viability for medical use.
Funding: $4.9M
Rough estimate of the amount of funding raised
Funding: $4.9M
Rough estimate of the amount of funding raised
The startup has developed a wearable wrist device that cools the skin on the inside of the wrist to modulate blood flow and alter thermal signals to the hypothalamus. This technology provides targeted relief for individuals experiencing hot flashes due to menopause.
Funding: $220.0K
Rough estimate of the amount of funding raised
Funding: $220.0K
Rough estimate of the amount of funding raised
Covatic utilizes on-device algorithms to enable privacy-focused, addressable advertising without collecting or processing personal data. This technology allows media companies to create targeted ad segments while minimizing regulatory risks and enhancing user trust.
Funding: $7.0M
Rough estimate of the amount of funding raised
Funding: $7.0M
Rough estimate of the amount of funding raised
The startup develops microbial detection technology that utilizes membrane-potential dynamics and electrical stimulation to differentiate between viable and incapacitated cells. This enables rapid identification of life-threatening microbes in medical settings and contamination in manufacturing processes, enhancing safety and efficiency.
Funding: $850.0K
Rough estimate of the amount of funding raised
Funding: $850.0K
Rough estimate of the amount of funding raised
Digistain provides an MHRA-cleared, UKCA-marked tumour profiling technology to assess the 10-year recurrence risk for ER+ breast cancer patients treated with endocrine therapy. This AI-enabled solution rapidly analyzes biopsy spectral signatures, generating a prognostic score in under one hour. The technology offers clinicians actionable insights to personalize treatment and avoid unnecessary adjuvant chemotherapy at a lower cost than traditional genomic assays.
Funding: $125.0K
Rough estimate of the amount of funding raised
Funding: $125.0K
Rough estimate of the amount of funding raised
Entia offers Liberty, a home-based blood monitoring solution that enables patients to conduct their own blood tests, including assessments of blood counts and liver function. This technology reduces the need for hospital visits and enhances personalized care pathways, improving patient engagement and clinical efficiency in cancer treatment.
Funding: $20.7M
Rough estimate of the amount of funding raised
Funding: $20.7M
Rough estimate of the amount of funding raised
Etcembly utilizes AI-driven protein language models to design and optimize T-cell receptors (TCRs) and antibodies, significantly enhancing the precision and safety of immunotherapy candidates for cancer treatment. The startup addresses the urgent need for faster drug discovery by leveraging extensive immune repertoire databases and advanced sequencing technologies to identify novel therapeutic targets.
Expend is an expense management platform that automates receipt and invoice processing, integrates with accounting software, and provides smart Mastercards for employee spending. It eliminates manual data entry errors and enhances visibility into company spending, significantly improving efficiency for finance teams and employees.
Funding: $1.3M
Rough estimate of the amount of funding raised
Funding: $1.3M
Rough estimate of the amount of funding raised
Flare Bright develops a GPS-free navigation system, the Software Enhanced Navigation System (SENS), that utilizes advanced inertial technology to enable aerial platforms to operate effectively in GPS-denied environments. This technology addresses the increasing threat of GPS spoofing and jamming, ensuring reliable navigation for commercial drone applications in critical sectors such as medical aid and agriculture.
Funding: $610.0K
Rough estimate of the amount of funding raised
Funding: $610.0K
Rough estimate of the amount of funding raised
GripAble develops digital therapy tools that utilize sensors to assess and train hand and arm movements, enhancing rehabilitation for physically impaired patients. By integrating engaging mobile games, GripAble improves patient adherence and outcomes while providing clinicians with objective progress tracking and documentation for optimal reimbursement.
Funding: $26.6M
Rough estimate of the amount of funding raised
Funding: $26.6M
Rough estimate of the amount of funding raised
HydRegen develops bio-based manufacturing technologies that replace toxic heavy-metal catalysts with robust biocatalysts, enabling chemical synthesis under mild conditions and in continuous flow. This approach reduces CO2 emissions by 30% and lowers production costs by 40%, enhancing safety and sustainability in chemical manufacturing.
Funding: $4.1M
Rough estimate of the amount of funding raised
Funding: $4.1M
Rough estimate of the amount of funding raised
Lucida Medical provides Pi™, an AI‑driven decision‑support platform that analyzes prostate MRI scans to detect clinically significant cancers with sensitivity and specificity comparable to expert radiologists. By delivering real‑time risk scores, automated lesion segmentation, and standardized reports that integrate with existing PACS and RIS systems, Pi™ enables same‑day biopsy scheduling for high‑risk patients, reducing diagnostic delays, unnecessary procedures, and overall pathway costs.
Funding: $517.8K
Rough estimate of the amount of funding raised
Funding: $517.8K
Rough estimate of the amount of funding raised
This company utilizes its proprietary HYBRID3D™ manufacturing platform to directly 3D print full-stack batteries with custom geometries. This process allows for energy to be integrated into product contours, maximizing interior volume utilization and achieving high energy density. The platform supports various chemistries and enables the creation of conformal energy solutions for diverse applications.
Metacarpal develops the world's first multi-articulated body-powered hand designed for upper-limb prosthetic users. This durable, waterproof device offers multiple grip patterns, including pinch, power, and lateral grips, providing reliable function without requiring external charging. The technology focuses on delivering dependable performance and intuitive control that integrates seamlessly into daily activities.
Funding: $1.1M
Rough estimate of the amount of funding raised
Funding: $1.1M
Rough estimate of the amount of funding raised
MitoRx Therapeutics develops first-in-class small molecule therapeutics that modulate mitochondrial metabolism to address cardiometabolic diseases, starting with obesity. Their platform utilizes targeted compounds to restore sulfide-signaling via enzymatic release within the mitochondria, reversing dysfunction. This approach aims to provide anti-obesogenic effects while preserving lean mass through adaptive metabolism restoration.
Funding: $6.9M
Rough estimate of the amount of funding raised
Funding: $6.9M
Rough estimate of the amount of funding raised
Neuroute utilizes advanced data analytics and machine learning algorithms to enhance the efficiency and transparency of clinical trial processes. The platform addresses the challenges of participant recruitment and retention, ultimately increasing diversity and improving trial outcomes.
Founded 2019
The startup develops a nanoparticle deposition system that enables precise and contamination-free application of nanoparticles for various uses, including drug delivery and catalysis. This technology provides life science researchers and industrial manufacturers with a reliable solution for their nanoparticle development and manufacturing needs.
Funding: $810.0K
Rough estimate of the amount of funding raised
Funding: $810.0K
Rough estimate of the amount of funding raised
ONI develops super-resolution microscopy tools, including the Nanoimager and Aplo Flow, to facilitate single-molecule imaging for researchers in various fields. Their technology simplifies sample preparation and data analysis, enabling more accurate and reproducible results in studies involving lipid nanoparticles and other biological samples.
Funding: $113.3M
Rough estimate of the amount of funding raised
Funding: $113.3M
Rough estimate of the amount of funding raised
The startup has developed a peptide identification and optimization platform that utilizes peptide bead display and ribonucleic acid display technologies to discover and present novel natural peptides. This platform enables clients to efficiently identify therapeutic candidates through high-throughput affinity and functional screening, addressing the need for biologically relevant peptide leads in drug development.
Funding: $17.2M
Rough estimate of the amount of funding raised
Funding: $17.2M
Rough estimate of the amount of funding raised
The startup has developed a biotechnology platform that enhances vaccine and gene therapy production by minimizing the generation of defective interfering particles (DIPs) throughout the manufacturing process. This technology enables manufacturers to maintain low DIP levels, improving the overall efficacy and yield of both live attenuated and inactivated viral vaccines.
Founded 2019
OXcan develops blood tests for early cancer detection utilizing advanced proteomics and artificial intelligence. The company focuses on improving diagnostic accuracy, particularly in complex areas like lung disease staging. This technology aims to enable earlier intervention and more effective curative treatment pathways for cancer patients.
Funding: $17.4M
Rough estimate of the amount of funding raised
Funding: $17.4M
Rough estimate of the amount of funding raised
The startup manufactures low-cost mechanical ventilators designed for emergency situations and low-resource settings, featuring rapid deployment and scalability. Their technology addresses the critical shortage of ventilators needed for both urgent medical care and routine procedures.
Funding: $330.0K
Rough estimate of the amount of funding raised
Funding: $330.0K
Rough estimate of the amount of funding raised
Showing 12 of 16 unmatched portfolio companies